PubRank

H Schuitemaker

Author PubWeight™ 124.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992 7.92
2 Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995 7.26
3 A new classification for HIV-1. Nature 1998 5.30
4 Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994 4.63
5 Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993 3.62
6 T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000 3.33
7 Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997 3.08
8 In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A 2000 2.78
9 Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995 2.24
10 Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999 2.09
11 Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001 2.05
12 Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998 1.88
13 The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994 1.85
14 Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992 1.81
15 Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995 1.79
16 OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001 1.75
17 Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J Virol 1998 1.63
18 Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999 1.61
19 HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999 1.55
20 T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today 1993 1.54
21 Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996 1.54
22 Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol 1998 1.52
23 Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS 2000 1.47
24 Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 1998 1.46
25 In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis 1998 1.40
26 Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000 1.35
27 Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest 2000 1.29
28 Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis 1999 1.26
29 Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol 2001 1.25
30 CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999 1.21
31 Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998 1.21
32 HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. J Clin Invest 1994 1.18
33 Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol 2000 1.14
34 Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle. J Virol 2000 1.12
35 Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol 2001 1.10
36 Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages. J Virol 1994 1.10
37 Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995 1.09
38 CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 2005 1.08
39 The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998 1.07
40 Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis 1998 1.07
41 Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. Immunol Today 1998 1.06
42 Broader tropism and higher cytopathicity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo. Virology 1996 1.05
43 Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. Virology 1999 1.04
44 No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999 1.03
45 Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J Virol 1995 1.02
46 Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol 1998 0.99
47 cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 1988 0.99
48 Resistance of surface-dried virus to common disinfection procedures. J Hosp Infect 2007 0.96
49 The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998 0.96
50 Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. Virology 2000 0.95
51 Virulent HIV strains? AIDS 1993 0.92
52 Viro-immunological studies in acute HIV-1 infection. AIDS 1994 0.91
53 Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. J Gen Virol 1998 0.90
54 Envelope V2 configuration and HIV-1 phenotype: clarification. Science 1995 0.90
55 Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. J Infect Dis 1998 0.90
56 Cytopathic effects of non-syncytium-inducing and syncytium-inducing human immunodeficiency virus type 1 variants on different CD4(+)-T-cell subsets are determined only by coreceptor expression. J Virol 2001 0.90
57 R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus. J Virol 1999 0.90
58 Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000 0.89
59 Kinetics of immune functions and virus replication during HIV-1 infection. Immunol Lett 1997 0.89
60 Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. AIDS 1998 0.87
61 Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J Infect Dis 1999 0.87
62 Effects of HIV-1 Tat protein on human T cell proliferation. Eur J Immunol 1992 0.86
63 Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples. J Virol 1998 0.86
64 Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants. AIDS Res Hum Retroviruses 1998 0.85
65 No selection for CCR5 coreceptor usage during parenteral transmission of macrophagetropic syncytium-inducing human immunodeficiency virus type 1. J Virol 2001 0.85
66 Viral safety of C1-inhibitor NF. Biologicals 2006 0.85
67 Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J Acquir Immune Defic Syndr Hum Retrovirol 1996 0.85
68 No difference in in vitro susceptibility to HIV type 1 between high-risk HIV-negative Ethiopian commercial sex workers and low-risk control subjects. AIDS Res Hum Retroviruses 2001 0.84
69 Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient. AIDS Res Hum Retroviruses 1995 0.83
70 Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. J Drug Target 1996 0.83
71 Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells. AIDS 2001 0.83
72 Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. AIDS 1998 0.82
73 Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. AIDS Res Hum Retroviruses 1995 0.82
74 Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J Virol 2000 0.81
75 The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. AIDS 2001 0.79
76 Temporal relationship between human immunodeficiency virus type 1 RNA levels in serum and cellular infectious load in peripheral blood. J Infect Dis 1997 0.79
77 Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest 1997 0.79
78 CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS. AIDS 1999 0.79
79 Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Biologicals 1998 0.78
80 HIV tropism. Nature 1993 0.78
81 Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins. AIDS Res Hum Retroviruses 1997 0.78
82 Analysis of CD8+ T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1997 0.78
83 The virucidal spectrum of a high concentration alcohol mixture. J Hosp Infect 2002 0.77
84 Molecular determinants of human immunodeficiency virus type I phenotype variability. Eur J Clin Invest 1996 0.76
85 Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. J Infect Dis 1996 0.76
86 Comment on Mosier and Sieburg. Immunol Today 1995 0.75
87 Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment. BioDrugs 1997 0.75
88 Normalization of the CD4 T cell receptor repertoire after evolution of syncytium-inducing HIV-1 variants. AIDS 2000 0.75
89 [Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]. Ned Tijdschr Geneeskd 1998 0.75